NASDAQ:TVTX Travere Therapeutics (TVTX) Stock Price, News & Analysis → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free TVTX Stock Alerts $5.34 -0.11 (-2.02%) (As of 01:03 PM ET) Add Compare Share Share Today's Range$5.12▼$5.5050-Day Range$5.45▼$8.7452-Week Range$5.12▼$22.75Volume636,218 shsAverage Volume1.26 million shsMarket Capitalization$406.43 millionP/E RatioN/ADividend YieldN/APrice Target$18.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Travere Therapeutics alerts: Email Address Travere Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside230.3% Upside$18.00 Price TargetShort InterestBearish13.93% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.76Based on 10 Articles This WeekInsider TradingSelling Shares$300,625 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.10) to ($1.85) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.42 out of 5 starsMedical Sector694th out of 907 stocksPharmaceutical Preparations Industry317th out of 422 stocks 3.3 Analyst's Opinion Consensus RatingTravere Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 9 buy ratings, 6 hold ratings, and no sell ratings.Amount of Analyst CoverageTravere Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted13.93% of the outstanding shares of Travere Therapeutics have been sold short.Short Interest Ratio / Days to CoverTravere Therapeutics has a short interest ratio ("days to cover") of 8.8.Change versus previous monthShort interest in Travere Therapeutics has recently increased by 5.26%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTravere Therapeutics does not currently pay a dividend.Dividend GrowthTravere Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TVTX. Previous Next 3.2 News and Social Media Coverage News SentimentTravere Therapeutics has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Travere Therapeutics this week, compared to 3 articles on an average week.Search Interest5 people have searched for TVTX on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Travere Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Travere Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $300,625.00 in company stock.Percentage Held by InsidersOnly 3.75% of the stock of Travere Therapeutics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Travere Therapeutics are expected to grow in the coming year, from ($3.10) to ($1.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Travere Therapeutics is -3.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Travere Therapeutics is -3.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTravere Therapeutics has a P/B Ratio of 2.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchMysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars. About Travere Therapeutics Stock (NASDAQ:TVTX)Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Read More TVTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TVTX Stock News HeadlinesApril 25, 2024 | americanbankingnews.comTravere Therapeutics (NASDAQ:TVTX) Price Target Increased to $19.00 by Analysts at HC WainwrightApril 24, 2024 | markets.businessinsider.comFILSPARI’s European Approval and Market Potential Bolster Buy Rating for Travere TherapeuticsApril 25, 2024 | Paradigm Press (Ad)Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISYou might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.April 24, 2024 | globenewswire.comTravere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA NephropathyApril 24, 2024 | prnewswire.comCSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA NephropathyApril 24, 2024 | americanbankingnews.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Receives Average Recommendation of "Moderate Buy" from AnalystsApril 18, 2024 | americanbankingnews.comTravere Therapeutics' (TVTX) Outperform Rating Reaffirmed at WedbushApril 14, 2024 | investing.comTravere Therapeutics CFO sells shares to cover tax obligationsApril 25, 2024 | Paradigm Press (Ad)Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISYou might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.April 4, 2024 | nz.finance.yahoo.comStock market today: Stocks slide after Fedspeak as oil surges, March jobs report on deckApril 4, 2024 | globenewswire.comTravere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians InternationalApril 3, 2024 | globenewswire.comTravere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses AssociationMarch 13, 2024 | globenewswire.comTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for Travere Therapeutics on Strong FILSPARI Data and Favorable Regulatory OutlookMarch 13, 2024 | markets.businessinsider.comPeeling Back The Layers: Exploring Travere Therapeutics Through Analyst InsightsMarch 11, 2024 | markets.businessinsider.comTravere Therapeutics Submits SNDA Seeking Full Approval Of Filspari In IgA NephropathyMarch 11, 2024 | markets.businessinsider.comTravere Therapeutics Submits SNDA Seeking Full Approval Of Filspari In IgA NephropathyMarch 11, 2024 | globenewswire.comTravere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)February 28, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Moderna (MRNA) and Travere Therapeutics (TVTX)February 26, 2024 | globenewswire.comTravere Therapeutics to Present at Upcoming Investor ConferencesFebruary 23, 2024 | markets.businessinsider.comBuy Rating Affirmed: Expanding Market Potential for Travere Therapeutics’ SparsentanFebruary 23, 2024 | msn.comTravere drug for rare kidney condition recommended for EU approvalFebruary 23, 2024 | globenewswire.comTravere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA NephropathyFebruary 18, 2024 | finance.yahoo.comTVTX Mar 2024 30.000 callFebruary 16, 2024 | finance.yahoo.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Q4 2023 Earnings Call TranscriptFebruary 16, 2024 | markets.businessinsider.comDeep Dive Into Travere Therapeutics Stock: Analyst Perspectives (7 Ratings)February 16, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Travere Therapeutics (TVTX) and Grifols SA (GRFS)See More Headlines Receive TVTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/15/2024Today4/25/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:TVTX CUSIPN/A CIK1438533 Webwww.retrophin.com Phone(888) 969-7879Fax302-645-1280Employees380Year FoundedN/APrice Target and Rating Average Stock Price Target$18.00 High Stock Price Target$35.00 Low Stock Price Target$9.00 Potential Upside/Downside+227.5%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($1.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-111,400,000.00 Net Margins-56.02% Pretax Margin-258.96% Return on Equity-177.97% Return on Assets-44.19% Debt Debt-to-Equity Ratio1.88 Current Ratio3.47 Quick Ratio3.41 Sales & Book Value Annual Sales$145.24 million Price / Sales2.86 Cash FlowN/A Price / Cash FlowN/A Book Value$2.67 per share Price / Book2.04Miscellaneous Outstanding Shares76,110,000Free Float73,019,000Market Cap$414.80 million OptionableOptionable Beta0.58 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Eric M. Dube Ph.D. (Age 50)President, CEO & Director Comp: $1.4MMr. Christopher Cline C.F.A. (Age 39)Chief Financial Officer Comp: $709.94kMs. Elizabeth E. Reed J.D. (Age 53)Senior VP, General Counsel & Corporate Secretary Comp: $713.63kDr. William E. Rote Ph.D. (Age 61)Senior VP and Head of Research & Development Comp: $748.02kMr. Peter Heerma (Age 52)Chief Commercial Officer Comp: $742.37kMs. Sandra Calvin (Age 58)SVP, Corporate Controller & Chief Accounting Officer Ms. Naomi EichenbaumVice President of Investor RelationsMs. Charlotte SmithSenior Vice President of Public AffairsMs. Angela GiannantonioSenior Vice President of Human ResourcesMr. Casey LoganChief Business OfficerMore ExecutivesKey CompetitorsEntrada TherapeuticsNASDAQ:TRDATheravance BiopharmaNASDAQ:TBPHShattuck LabsNASDAQ:STTKAvid BioservicesNASDAQ:CDMOAcelyrinNASDAQ:SLRNView All CompetitorsInsiders & InstitutionsAssenagon Asset Management S.A.Sold 35,371 shares on 4/24/2024Ownership: 0.287%Rice Hall James & Associates LLCBought 3,140 shares on 4/23/2024Ownership: 0.096%Hennion & Walsh Asset Management Inc.Bought 5,123 shares on 4/17/2024Ownership: 0.054%Christopher R ClineSold 54 sharesTotal: $363.96 ($6.74/share)Los Angeles Capital Management LLCBought 93,417 shares on 4/5/2024Ownership: 0.123%View All Insider TransactionsView All Institutional Transactions TVTX Stock Analysis - Frequently Asked Questions Should I buy or sell Travere Therapeutics stock right now? 15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Travere Therapeutics in the last twelve months. There are currently 6 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" TVTX shares. View TVTX analyst ratings or view top-rated stocks. What is Travere Therapeutics' stock price target for 2024? 15 brokers have issued 1-year target prices for Travere Therapeutics' stock. Their TVTX share price targets range from $9.00 to $35.00. On average, they predict the company's stock price to reach $18.00 in the next year. This suggests a possible upside of 230.3% from the stock's current price. View analysts price targets for TVTX or view top-rated stocks among Wall Street analysts. How have TVTX shares performed in 2024? Travere Therapeutics' stock was trading at $8.99 at the beginning of 2024. Since then, TVTX shares have decreased by 39.4% and is now trading at $5.45. View the best growth stocks for 2024 here. When is Travere Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our TVTX earnings forecast. How were Travere Therapeutics' earnings last quarter? Travere Therapeutics, Inc. (NASDAQ:TVTX) issued its quarterly earnings data on Thursday, February, 15th. The company reported ($1.16) earnings per share for the quarter, topping the consensus estimate of ($1.27) by $0.11. The business earned $45.06 million during the quarter, compared to analysts' expectations of $41.25 million. Travere Therapeutics had a negative trailing twelve-month return on equity of 177.97% and a negative net margin of 56.02%. What ETF holds Travere Therapeutics' stock? Virtus LifeSci Biotech Products ETF holds 44,150 shares of TVTX stock, representing 1.52% of its portfolio. Who are Travere Therapeutics' major shareholders? Travere Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (0.29%), Los Angeles Capital Management LLC (0.12%), Rice Hall James & Associates LLC (0.10%) and Hennion & Walsh Asset Management Inc. (0.05%). Insiders that own company stock include Christopher R Cline, Elizabeth E Reed, Eric M Dube, Jula Inrig, Laura Clague, Noah L Rosenberg, Peter Heerma, Sandra Calvin, Steve Aselage and William E Rote. View institutional ownership trends. How do I buy shares of Travere Therapeutics? Shares of TVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TVTX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.